Dolatrai Vyas Net Worth

The estimated Net Worth of Dolatrai Vyas is at least $447 Thousand dollars as of 21 June 2022. Dolatrai Vyas owns over 4,283 units of Spectrum Pharmaceuticals stock worth over $84,525 and over the last 11 years he sold SPPI stock worth over $105,370. In addition, he makes $257,115 as Independent Director at Spectrum Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dolatrai Vyas SPPI stock SEC Form 4 insiders trading

Dolatrai has made over 3 trades of the Spectrum Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,283 units of SPPI stock worth $3,384 on 21 June 2022.

The largest trade he's ever made was selling 9,000 units of Spectrum Pharmaceuticals stock on 17 June 2021 worth over $38,160. On average, Dolatrai trades about 1,206 units every 78 days since 2013. As of 21 June 2022 he still owns at least 82,063 units of Spectrum Pharmaceuticals stock.

You can see the complete history of Dolatrai Vyas stock trades at the bottom of the page.

Dolatrai Vyas biography

Dr. Dolatrai M. Vyas Ph.D. serves as Independent Director of the Company. Dr. Vyas has 31 years of tenure in oncology drug discovery research at Bristol-Myers Squibb Company (“BMS”), a pharmaceutical company, where he served in various positions, including most recently as a Group Director and Distinguished Research Fellow (Executive Level) in Oncology Discovery Chemistry. Dr. Vyas is considered one of the pioneers of the BMS oncology medicinal chemistry discovery efforts based on natural products derived cytotoxics. During this period, he was also involved in BMS’s pioneering research on antibody drug conjugate technology to target cytotoxics selectively to tumors. In the last 15 years of his oncology research career at BMS, he was involved in discovery and development of personalized medicine research involving small molecule molecular targeted oncology therapeutics. During his tenure at BMS, he has participated in the discovery and development of twelve small molecules and one biologic as clinical development candidates with one FDA-approved new drug application. Dr. Vyas retired from BMS in 2011 and subsequently formed a research and development consulting company, Dinesh Vyas, LLC.

What is the salary of Dolatrai Vyas?

As the Independent Director of Spectrum Pharmaceuticals, the total compensation of Dolatrai Vyas at Spectrum Pharmaceuticals is $257,115. There are 12 executives at Spectrum Pharmaceuticals getting paid more, with Joseph Turgeon having the highest compensation of $5,697,230.

How old is Dolatrai Vyas?

Dolatrai Vyas is 76, he's been the Independent Director of Spectrum Pharmaceuticals since 2013. There are no older and 14 younger executives at Spectrum Pharmaceuticals.

What's Dolatrai Vyas's mailing address?

Dolatrai's mailing address filed with the SEC is 11500 S. EASTERN AVE., SUITE 220, HENDERSON, NV, 89052.

Insiders trading at Spectrum Pharmaceuticals

Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, and Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.

What does Spectrum Pharmaceuticals do?

spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Complete history of Dolatrai Vyas stock trades at Spectrum Pharmaceuticals

Spectrum Pharmaceuticals executives and stock owners

Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Turgeon,
  President, Chief Executive Officer, Director
• Thomas Riga,
  Chief Operating Officer, Chief Commercial Officer, Executive Vice President
• Kurt Gustafson,
  Chief Financial Officer, Executive Vice President
• Keith McGahan,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Francois Lebel,
  Executive Vice President, Chief Medical Officer
• Thomas J. Riga,
  Pres, CEO & Director
• Kurt A. Gustafson,
  Exec. VP & CFO
• Dr. Francois J. Lebel FRCPC, M.D.,
  Exec. VP & Chief Medical Officer
• Keith M. McGahan J.D., L.L.M.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• William Ashton,
  Independent Chairman of the Board
• Bernice Welles,
  Independent Director
• Jeffrey Vacirca,
  Independent Director
• Dolatrai Vyas,
  Independent Director
• Elizabeth Czerepak,
  Independent Director
• Seth Fischer,
  Independent Director
• Lyndah Dreiling,
  Senior Vice President, Clinical Development
• Dr. Lyndah K. Dreiling M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Lisa A. Croissant,
  VP of Sales
• Alberto Dejesus,
  VP of Marketing
• Bimal R. Shah,
  VP of Corp. & Bus. Devel.
• Anthony E Iii Maida,
  Director
• Raymond W Cohen,
  Director
• Stuart Mitchell Krassner,
  Director
• Gilles Gagnon,
  Director
• Luigi Md Lenaz,
  President, Oncology Division
• Juhyun Lim,
  Director
• Jeff L Vacirca,
  Director
• Ann C Phd Kessler,
  Director
• Armin M Kessler,
  Director
• Lee F Md Ph D Allen,
  Chief Medical Officer
• Joseph Kenneth Keller,
  EVP & Chief Operating Officer
• Carol Phd Ocleireacain,
  Director
• Paul H Phd Silverman,
  Director
• Shyam K Kumaria,
  Vice President Finance
• Mark J Glasky,
  Director
• Krishan K Arora,
  Director
• Eric L Phd Nelson,
  Director
• John L Mcmanus,
  VP,Finance, Strategic Planning
• Rajesh C Md Shrotriya,
  Ch, Pres. and Chief Exec. Off.
• Julius A Vida,
  Director
• Dilip J Md Phd Mehta,
  Director
• Richard Fulmer,
  Director
• James Shields,
  Chief Commercial Officer
• Brett L Scott,
  Acting Chief Financial Officer
• Anton Gueth,
  Director
• Mitchell P. Cybulski,
  Director
• George F Tidmarsh,
  CSO AND HEAD OF R&D OPERATIONS
• Nora Brennan,
  See Remarks